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Introduction: Perivascular epithelioid cell tumors are mesenchymal tumors composed of histologically and
immunohistochemically distinctive perivascular epithelioid cells. This type of tumor is rare but bladder localization is
even rarer.
Case presentation: A case of bone metastatic bladder perivascular epithelioid cell tumor in a 65-year-old Caucasian
man treated with surgery and chemotherapy is described and compared with other reports in the literature.
Conclusions: The rarity of perivascular epithelioid cell tumors hinders the development of a standard therapeutic
approach, and thus requires case report descriptions. There is a need for cooperative studies to enlarge the case
series and establish the best treatment strategy for this rare disease.
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The World Health Organization describes perivascular
epithelioid cell tumors (PEComas) as “mesenchymal tu-
mors composed of histologically and immunohisto-
chemically distinctive perivascular epithelioid cells” [1].
The PEComa family of tumors includes angiomyoli-
poma, clear cell “sugar” tumor, lymphangioleiomyomato-
sis, and numerous unusual visceral, intra-abdominal, soft
tissue, and bone tumors. These have a variety of names,
including clear cell myomelanocytic tumor of the
falciform ligament/ligamentum teres, abdominopelvic
sarcoma of perivascular epithelioid cells, and primary
extrapulmonary sugar tumor, among others [2].
PEComas are rare and only 13 cases of bladder
localization have been reported in the literature [3]. We
describe a case of skeletal metastatic PEComa arising
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A 65-year-old Caucasian man (body mass index 25kg/m2)
had a history of ischemic heart disease and lower urinary
tract symptoms secondary to benign prostatic hyperplasia,
which was under pharmacological treatment with alpha-
blockers. He consulted us due to recurrent hematuria and
back pain that had been unsuccessfully treated with anti-
biotics and anti-inflammatory drugs in the previous 2
months. His physical examination was normal. A digital
rectal examination revealed a moderate increase in
prostatic gland size without any finding suspicious for
neoplastic disease.
The results of his blood tests were normal and his
total prostate-specific antigen value was 2.2ng/mL. An
abdominal ultrasound showed normal kidneys and a
lesion of his right bladder wall associated with a 2cm
calculus. On cystoscopy, his bladder lesion was a solid,
sessile, mass of 2.5cm on the right lateral wall, 3cm from
his right ureteral orifice; a 2cm bladder stone was con-
firmed. Abdominopelvic contrast computed tomography
(CT) showed mild heterogeneous enhancement of the
lesion, which infiltrated his bladder wall. No other
lesions or local or systemic adenopathy were observedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Computed tomography and transurethral resection of the bladder lesion. CT showed mild heterogeneous enhancement of the lesion,
which infiltrated the bladder wall, no other lesions or local or systemic adenopathy were observed (a–c). Transurethral resection of bladder (d).
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of the mass and a simultaneous transurethral cystolitho-
tripsy (Figure 1d).
No intra- and postoperative complications were ob-
served; he was discharged on the second postoperative
day after catheter removal. Histopathology of the lesion
showed spindled and epithelioid clear neoplastic cells
with prominent blood vessels (Figure 2a); immunohisto-
chemistry was positive for human melanoma black-45
and negative for S-100, vimentin, smooth muscle actin,
cytokeratin, and desmin (Figure 2b). The tissue exhibited
an infiltrative growth pattern with high mitotic activity
(more than 1/50 high-power field) and necrosis. These
findings were suggestive of a malignant PEComa.Figure 2 Microscopic examination (magnification 10×) showing a mix
blood vessels (a) and strong positivity for human melanoma black-45Based on the histopathological examination and nega-
tive CT findings with symptoms (persistent back pain),
positron emission tomography (PET) was performed,
which showed an increased uptake of the radiopharma-
ceutical drug at specific skeletal segments: somas of L1,
L5, and the left iliac wing. After surgery, he had a per-
formance status of 1 and reported a moderate pain in
his lumbar region with a visual analog scale (VAS; from
1 to 10) of 5. Chemotherapy was therefore planned. Pre-
vious ischemic heart disease and the echocardiographic
finding of reduced systolic function with first-degree dia-
stolic dysfunction prevented the use of anthracyclines,
which are the standard first-line treatment for soft tissue
sarcomas [4-10]. Gemcitabine was therefore administered,ture of epithelioid and spindle-shaped cells with prominent
at immunohistochemistry (b).
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1, 8, and 15 of a 4-week cycle. He was clinically re-
evaluated before each dose. His performance status did
not change during the treatment and pain in his lumbar
region disappeared after the third administration (VAS: 1).
The treatment was well tolerated and analgesics were not
necessary. Side effects were nausea, asthenia, moderate
thrombocytopenia (90,000 platelet count/mcL) and neu-
tropenia (4100 white blood cells/mcL).
Six months after starting chemotherapy, CT assess-
ment showed a stable disease according to the response
evaluation criteria in solid tumors; no bladder recur-
rence was observed on PET or cystoscopic control; skel-
etal metastases were reduced and no other secondary
lesions were observed. He is presently clinically stable.
Discussion
The definition of PEComa was suggested by Zamboni
et al. in 1996 to identify a group of mesenchymal neo-
plasms originating from perivascular epithelioid cells
[11]. However, only a few cases of urinary bladder
PEComa have been reported in the literature; fewer with
bone metastasis [12]. We therefore consider our case to
be of interest. The diagnosis of PEComa is based only
on histopathological examination because there are no
macroscopic features or imaging details that allow iden-
tification before surgical removal, which is mandatory.
Furthermore, given the rarity of these tumors, there is
no specific consensus regarding the ideal therapy after
surgery in case of bladder and other localizations. It is
still controversial whether these tumors can be consid-
ered benign or if they all carry some intrinsic risk of ag-
gressive behavior. In this regard, PEComas with a major
risk of progression are described by the Folpe criteria as
those >5cm, with infiltrative behavior, high nuclear grade,
high cellularity, high mitotic rate, presence of necrosis,
and vascular invasion [13].
Based on this classification, adding medical treatment
to surgery in patients with these histopathologic findings
is advisable. Unfortunately, the authors who reported
their experience of PEComas used different therapies
and reported different follow-up procedures, thus pre-
venting comparison of outcomes and assessment of a
standard protocol for treatment [4]. Specifically consid-
ering experience with bladder PEComas, all authors
report surgical removal as the first step in treatment
(endoscopic bladder resection, or partial or radical cyst-
ectomy), but postoperative medical management is still
poorly reported.
In the present case, gemcitabine was selected as
chemotherapy due to the patient’s cardiovascular disease,
which did not allow the use of drugs with cardiotoxic
risk. At present, he is clinically stable with no cysto-
scopic, PET, or CT evidence of disease progression, thusimplying good efficacy of our therapeutic approach.
Conversely, Parfitt et al. treated a bladder PEComa with
primary excision and adjuvant interferon-alpha immuno-
therapy with evidence of remission until 48 months of
follow-up [14]. No other adjuvant therapies specific for
bladder localization are described in literature to the
best of our knowledge.
In terms of medical treatment, even though not specif-
ically for bladder localization, encouraging outcomes
have been reported with administration of mammalian
target of rapamycin (mTor) inhibitors. In particular, a
case of retroperitoneal PEComa was reported in a man
with complete disease regression after treatment with
everolimus [15]. PEComas are related to the genetic al-
terations of tuberous sclerosis complex (TSC), an auto-
somal dominant genetic disease associated with losses of
TSC1 (9q34) or TSC2 (16p13.3) genes, which seem to
have a role in the regulation of the Rheb/mTOR/p70S6K
pathway.
However, as reported by Martignoni et al., it should be
noted that these approaches derive from anecdotal cases
as no therapeutic trial has so far been implemented due
to the rarity of the disease [16]. An international co-
operative study would enlarge the case series and help to
address this problem.Conclusions
The majority of bladder tumors are of urothelial origin
and, generally, small lesions are considered to have lim-
ited metastatic risk. However, the case reported here
shows that the histopathological characteristics of a
bladder tumor may sometimes be different and carry a
high metastatic risk.
PEComas are very rare, but they may occur in the
urinary bladder; the case reported here adds to the small
body of literature that demonstrates that they can
metastasize in different sites of the human body. Surgi-
cal removal remains the most important therapeutic ap-
proach while controversy is still ongoing about the best
postoperative therapeutic management. Based on the
large body of experience present in the literature on the
treatment of soft tissue tumors, the use of anthracyclines
could also be considered a good therapeutic option for
PEComas, but single-agent chemotherapy with gemcita-
bine should be considered an option in patients selected
for comorbidities until standard treatment protocols can
be generated from larger comparative trials.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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